Table 4.
Chemotherapy result of stage IV marginal zone B‐cell lymphoma
| Rituximab (−) (N = 31) | Rituximab (+) (N = 31) | P† | |
|---|---|---|---|
| Characteristics | |||
| Male/Female | 16/15 | 21/10 | 0.300 |
| Age <60/≥60 (years) | 14/17 | 17/14 | 0.612 |
| LN involvement −/+ | 5/26 | 9/22 | 0.363 |
| Hb ≥/<12 g/dL | 12/16 | 18/7 | 0.052 |
| ALC ≥/<1.0 × 109/L | 19/9 | 20/5 | 0.365 |
| PS (ECOG) 0–1/2 | 28/3 | 28/3 | 1.000 |
| BM involvement −/+ | 8/23 | 11/17 | 0.403 |
| MM‐MZL −/+ | 9/22 | 11/20 | 0.786 |
| IPI 0–2/3–5 | 25/13 | 13/16 | 0.257 |
| Regimen | |||
| CVP | 15 | 23 | 0.056 |
| CHOP | 13 | 6 | |
| Others | 3‡ | 2§ | |
| Median cycle (range) | 6 (1–12) | 8 (1–9) | |
| Response | |||
| CR | 11 | 19 | 0.026 |
| PR | 6 | 7 | |
| SD | 7 | 3 | |
| PD | 5 | 1 | |
| NE | 2 | 1 | |
†P‐value by χ2 test. ‡Chloambucil, 1; fludarabine, 2.
§Rituximab monotherapy, 1; Zevalin, 1. Bold values denote statistical significance. ALC, absolute lymphocyte count; BM, bone marrow; CHOP, Cyclophosphamide + Doxorubicin + Vincristine + Prednisone; CR, complete response; CVP, Cyclophosphamide + Vincristine + Prednisone; Hb, hemoglobin; IPI, International Prognostic Index; LN, lymph node; (MM)‐MZL, (multiple‐mucosa‐associated lymphoid tissue (MALT)‐organs‐involved)‐marginal zone B‐cell lymphoma; NE, not evaluable; PD, progression of disease; PR, partial response; PS (ECOG), Eastern Cooperative Oncology Group Performance Status; SD, stable disease; −/+, no/yes.